Cisplatin (Head and Neck Cancer) Analysis and Forecasts to 2020


#28375

41pages

GlobalData

$ 2000

In Stock


Summary

GlobalDatas pharmaceuticals report, Cisplatin (Head and Neck Cancer) Analysis and Forecasts to 2020 provides Cisplatin sales estimates for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Head and Neck Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

 

  • Therapy area profile including patient population for the Japan (seven major markets)
  • Analysis and review of Cisplatin including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Cisplatin including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Cisplatin in the Japan

Reasons to buy

 

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

 

Table of Contents

 

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 Head and Neck Cancer Market 4
2.2 Epidemiology 4
2.3 Etiology 9
2.4 GlobalData Pipeline Report Guidance 10


3 Head and Neck Cancer Disease: Market Characterization 11
3.1 Head and Neck Cancer Disease Market 11
3.2 Head and Neck Cancer Disease Market Forecasts and CAGR 11
3.3 Drivers for the Head and Neck Cancer Disease Market 12
3.3.1 High Incidence 12
3.3.2 Low Initial Diagnosis Rate 13
3.3.3 Emergence of Targeted Therapies and Vaccines 13


4 Tumor NodeMetastases (TNM) Classification of Head and Neck Cancer 14


5 Cisplatin 22
5.1 Introduction 22
5.2 Mechanism of Action 22
5.3 Clinical Studies 22
5.4 Approval History of Cisplatin 23
5.5 Factors Affecting Sales of Cisplatin 23
5.5.1 Head and Neck Cancer Market 23
5.5.2 Low Competition 23
5.5.3 Dominance of Platinum Drug Cisplatin 23
5.5.4 Beneficial for both Locally Advanced and Metastatic Patients 24
5.5.5 Prescribed in All Combinations 24
5.6 Drug Risk Benefit Score 24
5.6.1 Efficacy 24
5.6.2 Safety 25
5.6.3 Compliance 25
5.6.4 Dosing Convenience 25
5.7 Intensity of Competition 25
5.8 Sales forecast 25
6.2.1 Target Patient Pool of Cisplatin 25
6.2.2 Dosing 26
6.2.3 Market Penetration 26
6.2.4 Annual Cost of Therapy 27
5.8.1 Sales Projections of Cisplatin 27


6 Head and Neck Cancer Market: Appendix 36
6.1 Market Definitions 36
6.2 Abbreviations 36
6.3 Research Methodology 37
6.3.1 Coverage 37
6.3.2 Secondary Research 38
6.3.3 Forecasting 38
6.3.4 Number of Patients Approved to take the Drug 38
6.3.5 Net Penetration of Drug 38
6.3.6 Net Annual Dosing 40
6.3.7 Annual Cost of Therapy 40
6.3.8 Primary Research 40
6.3.9 Expert Panels 40
6.4 Contact Us 40
6.5 Disclaimer 40
6.6 Sources 41


Table 1: Head and Neck Cancer, Incidences and Mortality, 2008-2030 5
Table 2: Head and Neck Cancer, Global, Market Forecasts($bn), 20092020 11
Table 3: TNM Classification of the Oral cavity, Larynx, Oropharynx and Hypopharyngeal Cancers 14
Table 4: TNM Classification of the Nasopharyngeal Cancer 19
Table 5: Clinical trials of Cisplatin in Combination with Marketed Drugs 22
Table 6: Clinical trials of Cisplatin in Combination with Pipeline Drugs 23
Table 7: Drug Risk Benefit Score of Cisplatin 24
Table 8: Annual Cost of Therapy 27
Table 9: Head and Neck Cancer, Global, Estimated Sales of Cisplatin ($m) 2002-2020 28
Table 10: Head and Neck Cancer, the US, Estimated Sales of Cisplatin ($m) 2002-2020 30
Table 11: Head and Neck Cancer, the UK, Estimated Sales of Cisplatin ($m) 2002-2020 31
Table 12: Head and Neck Cancer, France, Estimated Sales of Cisplatin ($m) 2002-2020 32
Table 13: Head and Neck Cancer, Germany, Estimated Sales of Cisplatin ($m) 2002-2020 33
Table 14: Head and Neck Cancer, Italy, Estimated Sales of Cisplatin ($m) 2002-2020 34
Table 15: Head and Neck Cancer, Spain, Estimated Sales of Cisplatin ($m) 2002-2020 35
Table 16: Head and Neck Cancer, Japan, Estimated Sales of Cisplatin ($m) 2002-2020 36


Figure 1: Percentage Distribution of Top 20 Cancers, Based on Incidence Global, 2008 6
Figure 2: Percentage Distribution of Top 20 Cancers, Based on Mortality Global, 2008 7
Figure 3: Difference Between Percentage Distribution of Incidence and Mortality of Top 20 Cancers , 2008 7
Figure 4: Percentage Distribution of Various Cancer Types in Head and Neck Considering US, EU-5 and Japan Incidence, 2008 8
Figure 5: Percentage Distribution of Various Cancer Types in Head and Neck Considering Global Incidence, 2008 8
Figure 6: Per Capita Cigarette Consumption Curve, the US, 1976-2006 9
Figure 7: Head and Neck Cancer, Global, Market Forecasts ($bn), 20092020 11
Figure 8: All Cancer Incidence, Global, 2008-2030 12
Figure 9: Head and Neck Cancer Incidence, Global, 2008-2030 12
Figure 10: Broad Classification of Head and Neck Cancer 14
Figure 11: : Detailed TNM Classification of Oral Cavity Cancer 15
Figure 12: Detailed TNM Classification of Laryngeal Cancer 16
Figure 13: Detailed TNM Classification of Oropharyngeal Cancer 17
Figure 14: Detailed TNM Classification of Hypopharyngeal Cancer 18
Figure 15: Detailed TNM Classification of Nasopharyngeal Cancer 20
Figure 16: Classification of Head and Neck Cancer 20
Figure 17: Drug Model Diagram of Cisplatin in the US, EU-5 and Japan 26
Figure 18: Head and Neck Cancer, Global, Estimated Sales of Cisplatin ($m) 2002-2020 28
Figure 19: Head and Neck Cancer, the US, EU and Japan, Cisplatin Sales Distribution, 2010 28
Figure 20: Head and Neck Cancer, the US, Estimated Sales of Cisplatin ($m) 2002-2020 29
Figure 21: Head and Neck Cancer, the UK, Estimated Sales of Cisplatin ($m) 2002-2020 30
Figure 22: Head and Neck Cancer, France, Estimated Sales of Cisplatin ($m) 2002-2020 31
Figure 23: Head and Neck Cancer, Germany, Estimated Sales of Cisplatin ($m) 2002-2020 32
Figure 24: Head and Neck Cancer, Italy, Estimated Sales of Cisplatin ($m) 2002-2020 33
Figure 25: Head and Neck Cancer, Spain, Estimated Sales of Cisplatin ($m) 2002-2020 34
Figure 26: Head and Neck Cancer, Japan, Estimated Sales of Cisplatin ($m) 2002-2020 35
Figure 27: GlobalData Methodology 37
Figure 28: Drug Model Diagram 39
Figure 29: Patients Approved for the Drug 39